Skip to main content
Back
Watch Compare

Immix Biopharma, Inc.

Data quality: 100%
IMMX
Nasdaq Manufacturing Chemicals
$9.65
▲ $0.90 (10.23%)
Mkt Cap: 511.30 M
Price
$9.65
Mkt Cap
511.30 M
Day Range
$8.72 — $10.07
52-Week Range
$1.36 — $11.61
Volume
765,405
Open $8.75
50D / 200D Avg
$8.11
18.91% above
50D / 200D Avg
$4.54
112.23% above

Quick Summary

Key Takeaways

Negative free cash flow of -24.66 M
Capital efficient — spends only 3.66% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-455.78%
Below sector avg (-53.47%)
ROIC-318.61%
Net Margin-147.19%
Op. Margin-149.78%

Safety

Debt / Equity
N/A
Current Ratio1.53
Interest CoverageN/A

Valuation

PE (TTM)
-17.37
Below sector avg (-1.47)
P/B Ratio61.86
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -17.4 -1.5
P/B 61.9 1.6
ROE % -455.8 -53.5
Net Margin % -147.2 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.00% Revenue Growth (3Y) 0.00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 20.00 M Net Income (TTM) -29.44 M
ROE -455.78% ROA -164.85%
Gross Margin N/A Operating Margin -149.78%
Net Margin -147.19% Free Cash Flow (TTM) -24.66 M
ROIC -318.61% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.53
Interest Coverage N/A Asset Turnover 1.12
Working Capital 5.73 M Tangible Book Value 8.26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -17.37 Forward P/E N/A
P/B Ratio 61.86 P/S Ratio 25.57
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -4.82%
Market Cap 511.30 M Enterprise Value 495.35 M
Per Share
EPS (Diluted TTM) -0.89 Revenue / Share 0.38
FCF / Share -0.47 OCF / Share -0.45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3.66% FCF Conversion 83.78%
SBC-Adj. FCF -27.27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 20.00 M 20.00 M 20.00 M — —
Net Income -29.44 M -21.61 M -15.43 M -8.23 M -24.38 M
EPS (Diluted) -0.89 -0.76 -0.89 — —
Gross Profit — — — — —
Operating Income -29.96 M -22.67 M -16.14 M -8.22 M -1.35 M
EBITDA — — — — —
R&D Expenses 16.26 M 11.29 M 8.74 M 4.20 M 126,527.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 497.0 497.0 179,853.0
Income Tax 37,724.0 41,037.0 26,415.0 10,268.0 6,013.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 104.84 M 22.95 M 19.93 M 14.91 M 18.19 M
Total Liabilities 11.04 M 9.70 M 3.72 M 1.75 M 202,039.0
Shareholders' Equity 93.80 M 13.25 M 16.41 M 13.16 M 17.99 M
Total Debt — — — — —
Cash & Equivalents 93.93 M 17.68 M 17.51 M 13.44 M 17.64 M
Current Assets 101.24 M 20.20 M 19.79 M 14.90 M 18.19 M
Current Liabilities 10.11 M 8.69 M 3.72 M 1.27 M 202,039.0